Den europeiske union - portugisisk - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - agentes antineoplásicos - poteligeo é indicado para o tratamento de pacientes adultos com micose fungóide (mf) ou síndrome de sézary (ss) que receberam pelo menos uma antes da terapia sistêmica.

Den europeiske union - portugisisk - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Den europeiske union - portugisisk - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, célula falciforme - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

merck sharp & dohme farmaceutica ltda. - pembrolizumabe - outros antineoplasicos

Den europeiske union - portugisisk - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Den europeiske union - portugisisk - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - neoplasias prostáticas - radiofármaco de diagnóstico - este medicamento é apenas para uso diagnóstico. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - ustequinumabe - imunosupressor

Portugal - portugisisk - DGAV (Direção Geral de Alimentação e Veterinária)

msd animal health, lda. - butorfanol 10.0 mg - solução injetável - butorfanol - equinos (cavalos), caninos (cães), felinos (gatos)

Portugal - portugisisk - DGAV (Direção Geral de Alimentação e Veterinária)

richter pharma ag - butorfanol 10.0 mg - solução injetável - butorfanol - equinos (cavalos), caninos (cães), felinos (gatos)

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - sulfato de morfina pentaidratado - analgesicos narcoticos